Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Mar. 31, 2023 | Apr. 30, 2023 | |
Document Information [Line Items] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2023 | |
Document Transition Report | false | |
Entity File Number | 001-15401 | |
Entity Registrant Name | EDGEWELL PERSONAL CARE COMPANY | |
Entity Incorporation, State or Country Code | MO | |
Entity Tax Identification Number | 43-1863181 | |
Entity Address, Address Line One | 6 Research Drive | |
Entity Address, City or Town | Shelton, | |
Entity Address, State or Province | CT | |
Entity Address, Postal Zip Code | 06484 | |
City Area Code | (203) | |
Local Phone Number | 944-5500 | |
Title of 12(b) Security | Common Stock, par value $0.01 per share | |
Trading Symbol | EPC | |
Security Exchange Name | NYSE | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 51,173,405 | |
Entity Central Index Key | 0001096752 | |
Current Fiscal Year End Date | --09-30 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Earnings and Comprehensive Income - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement [Abstract] | ||||
Net sales | $ 598.4 | $ 547.7 | $ 1,067.5 | $ 1,011 |
Cost of products sold | 356.7 | 317.6 | 636.8 | 591 |
Gross profit | 241.7 | 230.1 | 430.7 | 420 |
Selling, general and administrative expense | 105.2 | 101.3 | 200.9 | 198.2 |
Advertising and sales promotion expense | 62.9 | 69.9 | 108.8 | 116.1 |
Research and development expense | 14.4 | 13.7 | 27.8 | 26.5 |
Restructuring charges | 3 | 3.5 | 5.8 | 5.7 |
Operating income | 56.2 | 41.7 | 87.5 | 73.5 |
Interest expense associated with debt | 20.7 | 18 | 40.6 | 35.3 |
Other expense (income), net | 9.5 | (3.4) | 4.5 | (5.1) |
Earnings before income taxes | 26 | 27.1 | 42.4 | 43.3 |
Income tax provision | 7 | 3.9 | 11.5 | 8.9 |
Net earnings | $ 19 | $ 23.2 | $ 30.9 | 34.4 |
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax | $ (15.9) | |||
Basic net earnings per share | $ 0.37 | $ 0.43 | $ 0.60 | $ 0.64 |
Diluted net earnings per share | $ 0.37 | $ 0.43 | $ 0.60 | $ 0.63 |
Condensed Consolidated Statements of Comprehensive Income | ||||
Net earnings | $ 19 | $ 23.2 | $ 30.9 | $ 34.4 |
Other comprehensive income (loss), net of tax | ||||
Foreign currency translation adjustments | 12.1 | (9) | 60.1 | |
Pension and postretirement activity, net of tax | 4.5 | 4.3 | 0.1 | |
Deferred gain (loss) on hedging activity, net of tax | 0.2 | 1 | (8) | 1.4 |
Total other comprehensive income (loss), net of tax | 16.8 | (7.9) | 56.4 | (14.4) |
Total comprehensive income | $ 35.8 | $ 15.3 | 87.3 | $ 20 |
Restructuring and related costs | $ 5.7 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Earnings and Comprehensive Income (Parenthetical) - USD ($) $ in Millions | 6 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement [Abstract] | ||
Pension and postretirement activity, tax | $ 1.6 | $ 0.2 |
Deferred gain on hedging activity, tax | $ 0.1 | $ 0.5 |
Diluted net earnings per share | $ 0.60 | $ 0.63 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 |
Current assets | ||
Cash and cash equivalents | $ 155.2 | $ 188.7 |
Trade receivables, less allowance for doubtful accounts | 160.8 | 136.9 |
Inventories | 540.5 | 449.3 |
Other current assets | 152.7 | 167.3 |
Total current assets | 1,009.2 | 942.2 |
Property, plant and equipment, net | 342.3 | 345.5 |
Goodwill | 1,333.6 | 1,322.2 |
Other intangible assets, net | 990.1 | 996.6 |
Other assets | 123.4 | 106.6 |
Total assets | 3,798.6 | 3,713.1 |
Current liabilities | ||
Notes payable | 21.5 | 19 |
Accounts payable | 245.1 | 237.3 |
Other current liabilities | 302.4 | 291.7 |
Total current liabilities | 569 | 548 |
Long-term debt | 1,413.6 | 1,391.4 |
Deferred income tax liabilities | 141.6 | 140.4 |
Other liabilities | 167.4 | 173.6 |
Liabilities, Total | 2,291.6 | 2,253.4 |
Shareholders’ equity | ||
Preferred shares | 0 | 0 |
Common shares | 0.7 | 0.7 |
Additional paid-in capital | 1,583.2 | 1,604.3 |
Retained earnings | 946.4 | 931.7 |
Common shares in treasury at cost | (863.6) | (860.9) |
Accumulated other comprehensive loss | (159.7) | (216.1) |
Total shareholders’ equity | 1,507 | 1,459.7 |
Total liabilities and shareholders’ equity | $ 3,798.6 | $ 3,713.1 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2023 | Sep. 30, 2022 |
Statement of Financial Position [Abstract] | ||
Preferred shares, par value (in usd per share) | $ 0.01 | $ 0.01 |
Preferred shares, authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred shares, issued (in shares) | 0 | 0 |
Preferred shares, outstanding (in shares) | 0 | 0 |
Common shares, par value (in usd per share) | $ 0.01 | $ 0.01 |
Common shares, authorized (in shares) | 300,000,000 | 300,000,000 |
Common shares, issued (in shares) | 65,251,989 | 65,251,989 |
Common shares, outstanding (in shares) | 51,215,845 | 51,573,001 |
Treasury Stock, Common, Shares | 14,036,144 | 13,678,988 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions | 6 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Cash Flow from Operating Activities | ||
Net earnings | $ 30.9 | $ 34.4 |
Depreciation and amortization | 45.6 | 44.6 |
Share-based compensation expense | 13.3 | 12.2 |
Loss on sale of assets | 1 | 0.4 |
Defined Benefit Plan, Benefit Obligation, Payment for Settlement | 7.2 | |
Deferred compensation payments | (4.7) | (7.1) |
Deferred income taxes | (0.9) | (10.5) |
Proceeds (payments) for other operating activities | (71.1) | (113) |
Other, net | (19.4) | (0.9) |
Net cash from (used by) operating activities | 1.9 | (39.9) |
Cash Flow from Investing Activities | ||
Capital expenditures | (18.8) | (25) |
Acquisition of Billie, net of cash acquired | 0 | 309.4 |
Collection of deferred purchase price on accounts receivable sold | 0.8 | 4.7 |
Proceeds from sale of Infant and Pet Care business | (2) | (1) |
Other, net | 0 | 5 |
Net cash used by investing activities | (20) | (325.7) |
Cash Flow from Financing Activities | ||
Cash proceeds from debt with original maturities greater than 90 days | 413 | 399 |
Cash payments on debt with original maturities greater than 90 days | (392) | (220) |
(Payments) proceeds of debt with original maturities of 90 days or less | (1.4) | 0.7 |
Repurchase of shares | (30) | (75.4) |
Dividends to common shareholders | (16.1) | (16.7) |
Net financing inflow (outflow) from the Accounts Receivable Facility | 4.8 | (0.2) |
Employee shares withheld for taxes | (8.1) | (9.7) |
Proceeds (payments) for other financing activities | 0.8 | 0.6 |
Net cash (used by) from financing activities | (29) | 78.3 |
Effect of exchange rate changes on cash | 13.6 | (3.8) |
Net decrease in cash and cash equivalents | (33.5) | (291.1) |
Cash and cash equivalents, beginning of period | 188.7 | 479.2 |
Cash and cash equivalents, end of period | $ 155.2 | $ 188.1 |
Condensed Consolidated Statem_4
Condensed Consolidated Statement of Changes in Shareholders' Equity Statement - USD ($) $ in Millions | Total | Reclassification out of Accumulated Other Comprehensive Income | Other expense (income), net Reclassification out of Accumulated Other Comprehensive Income | Common shares | Treasury Stock, Common | Additional paid-in capital | Retained earnings | Accumulated other comprehensive loss |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Treasury Stock, Common, Shares | (10,900,000) | |||||||
Common shares, issued (in shares) | 65,200,000 | |||||||
Treasury Stock, Common, Shares | (10,900,000) | |||||||
Beginning shareholders' equity at Sep. 30, 2021 | $ 1,584.3 | $ 0.7 | $ (776.3) | $ 1,631.1 | $ 865.7 | $ (136.9) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net earnings | 11.2 | 23.2 | ||||||
Foreign currency translation adjustments | (6.9) | (9) | ||||||
Pension and postretirement activity, net of tax | 0.1 | 0.1 | ||||||
Deferred gain (loss) on hedging activity, net of tax | 0.4 | 1 | ||||||
Dividends declared to common shareholders | (8.2) | (8.2) | ||||||
Activity under share plans (shares) | 100,000 | |||||||
Activity under share plans (in usd) | 7 | $ 3.5 | ||||||
APIC activity under share plans | 3.5 | |||||||
Ending shareholders' equity at Dec. 31, 2021 | 1,515.5 | 0.7 | (814.6) | 1,597.2 | 883.5 | (151.3) | ||
Beginning shareholders' equity at Sep. 30, 2021 | 1,584.3 | 0.7 | (776.3) | 1,631.1 | 865.7 | (136.9) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net earnings | 34.4 | 11.2 | ||||||
Foreign currency translation adjustments | (6.9) | |||||||
Pension and postretirement activity, net of tax | 0.1 | |||||||
Deferred gain (loss) on hedging activity, net of tax | 1.4 | 0.4 | ||||||
Dividends declared to common shareholders | (8.4) | (8.4) | ||||||
Treasury shares repurchased (in usd) | (24.5) | $ (24.5) | ||||||
Treasury shares repurchased (in shares) | (500,000) | |||||||
Activity under share plans (shares) | 300,000 | |||||||
Activity under share plans (in usd) | (3.8) | $ 33.6 | ||||||
APIC activity under share plans | (37.4) | |||||||
Ending shareholders' equity at Mar. 31, 2022 | 1,552.3 | $ 0.7 | $ (767.2) | 1,593.7 | 868.5 | (143.4) | ||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||
OCI Cash flow hedges reclass to earnings, before tax | $ 2.9 | |||||||
Treasury Stock, Common, Shares | (12,400,000) | |||||||
Common shares, issued (in shares) | 65,200,000 | |||||||
Treasury Stock, Common, Shares | (12,400,000) | |||||||
Beginning shareholders' equity at Dec. 31, 2021 | 1,515.5 | $ 0.7 | $ (814.6) | 1,597.2 | 883.5 | (151.3) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net earnings | 23.2 | |||||||
Foreign currency translation adjustments | (9) | |||||||
Deferred gain (loss) on hedging activity, net of tax | 1 | |||||||
Treasury shares repurchased (in usd) | $ (50.9) | |||||||
Treasury shares repurchased (in shares) | (1,400,000) | |||||||
Ending shareholders' equity at Mar. 31, 2022 | $ 1,552.3 | $ 0.7 | $ (767.2) | 1,593.7 | 868.5 | (143.4) | ||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||
OCI Cash flow hedges reclass to earnings, before tax | $ 1.6 | |||||||
Treasury Stock, Common, Shares | (11,100,000) | |||||||
Common shares, issued (in shares) | 65,200,000 | |||||||
Treasury Stock, Common, Shares | (11,100,000) | |||||||
Treasury Stock, Common, Shares | 13,678,988 | (13,700,000) | ||||||
Common shares, issued (in shares) | 65,251,989 | 65,200,000 | ||||||
Treasury Stock, Common, Shares | 13,678,988 | (13,700,000) | ||||||
Beginning shareholders' equity at Sep. 30, 2022 | $ 1,459.7 | $ 0.7 | $ (860.9) | 1,604.3 | 931.7 | (216.1) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net earnings | 11.9 | 19 | ||||||
Foreign currency translation adjustments | 48 | 12.1 | ||||||
Pension and postretirement activity, net of tax | (0.2) | 4.5 | ||||||
Deferred gain (loss) on hedging activity, net of tax | (8.2) | 0.2 | ||||||
Dividends declared to common shareholders | (8.2) | (8.2) | ||||||
Treasury shares repurchased (in usd) | (15) | $ (15) | ||||||
Treasury shares repurchased (in shares) | (400,000) | |||||||
Activity under share plans (shares) | 0 | |||||||
Activity under share plans (in usd) | 7.7 | $ 2.3 | ||||||
APIC activity under share plans | 5.4 | |||||||
Ending shareholders' equity at Dec. 31, 2022 | 1,486.7 | 0.7 | (863.6) | 1,583.2 | 946.4 | (159.7) | ||
Beginning shareholders' equity at Sep. 30, 2022 | 1,459.7 | 0.7 | (860.9) | 1,604.3 | 931.7 | (216.1) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net earnings | 30.9 | (11.9) | ||||||
Foreign currency translation adjustments | 60.1 | 48 | ||||||
Pension and postretirement activity, net of tax | 4.3 | (0.2) | ||||||
Deferred gain (loss) on hedging activity, net of tax | (8) | (8.2) | ||||||
Dividends declared to common shareholders | (8) | (8) | ||||||
Treasury shares repurchased (in usd) | $ (30) | $ (15) | ||||||
Treasury shares repurchased (in shares) | (800,000) | (400,000) | ||||||
Activity under share plans (shares) | 400,000 | |||||||
Activity under share plans (in usd) | $ (1.5) | $ 25 | ||||||
APIC activity under share plans | (26.5) | |||||||
Ending shareholders' equity at Mar. 31, 2023 | 1,507 | $ 0.7 | $ (850.9) | 1,577.8 | 935.6 | (176.5) | ||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||
OCI Cash flow hedges reclass to earnings, before tax | $ 5.8 | |||||||
Treasury Stock, Common, Shares | (14,100,000) | |||||||
Common shares, issued (in shares) | 65,200,000 | |||||||
Treasury Stock, Common, Shares | (14,100,000) | |||||||
Beginning shareholders' equity at Dec. 31, 2022 | 1,486.7 | $ 0.7 | $ (863.6) | 1,583.2 | 946.4 | (159.7) | ||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net earnings | 19 | |||||||
Foreign currency translation adjustments | 12.1 | |||||||
Pension and postretirement activity, net of tax | 4.5 | |||||||
Deferred gain (loss) on hedging activity, net of tax | 0.2 | |||||||
Ending shareholders' equity at Mar. 31, 2023 | $ 1,507 | $ 0.7 | $ (850.9) | $ 1,577.8 | $ 935.6 | $ (176.5) | ||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||
OCI Cash flow hedges reclass to earnings, before tax | $ 0.8 | |||||||
Treasury Stock, Common, Shares | 14,036,144 | (13,700,000) | ||||||
Common shares, issued (in shares) | 65,251,989 | 65,200,000 | ||||||
Treasury Stock, Common, Shares | 14,036,144 | (13,700,000) |
Background and Basis of Present
Background and Basis of Presentation | 6 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Background and Basis of Presentation | Background and Basis of Presentation Background Edgewell Personal Care Company and its subsidiaries (collectively, “Edgewell” or the “Company”) is one of the world’s largest manufacturers and marketers of personal care products in the wet shave, sun and skin care, and feminine care categories. With operations in over 20 countries and with products widely available in more than 50 countries. The Company conducts its business in the following three segments: • Wet Shave consists of products sold under the Schick®, Wilkinson Sword®, Edge, Skintimate®, Billie®, Shave Guard and Personna® brands, as well as non-branded products. The Company’s wet shave products include razor handles and refillable blades, disposable shave products, and shaving gels and creams. • Sun and Skin Care consists of Banana Boat® and Hawaiian Tropic® sun care products, Jack Black®, Bulldog® and Cremo® men’s grooming products, Billie women’s grooming products and Wet Ones® products. • Feminine Care includes tampons, pads, and liners sold under the Playtex Gentle Glide® and Sport®, Stayfree®, Carefree®, and o.b.® brands. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its controlled subsidiaries and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) under the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). The preparation of the unaudited Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results may differ materially from those estimates. All intercompany balances and transactions have been eliminated in consolidation and, in the opinion of management, all normal recurring adjustments considered necessary for a fair statement have been included in the interim results reported. The fiscal year-end balance sheet data was derived from audited consolidated financial statements, but do not include all of the annual disclosures required by GAAP; accordingly, these unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited annual consolidated financial statements included in its Annual Report on Form 10-K filed with the SEC on November 16, 2022. Acquisition of Billie, Inc. On November 29, 2021 (“the Acquisition Date”), the Company completed the acquisition of Billie, Inc. (“Billie”) (the “Acquisition”), a leading U.S. based consumer brand company that offers a broad portfolio of personal care products for women. The results of Billie for the post-acquisition period are included within the Company’s results since the acquisition date. For more information on the Acquisition, see Note 2 of Notes to Condensed Consolidated Financial Statements. |
Business Combinations
Business Combinations | 6 Months Ended |
Mar. 31, 2023 | |
Business Combinations [Abstract] | |
Business Combinations and Divestitures | Business Combinations Billie Inc. The Company completed the Acquisition for cash consideration of $309.4, net of cash acquired. As a result of the Acquisition, Billie became a wholly owned subsidiary of the Company. The Company accounted for the Acquisition utilizing the acquisition method of accounting, which requires assets and liabilities to be recognized based on estimates of their acquisition date fair values. The determination of the values of the acquired assets and assumed liabilities, including goodwill, other intangible assets and deferred taxes, requires significant judgement. The Company has calculated fair values of the assets and liabilities acquired from Billie, including goodwill, intangible assets and working capital. The Company completed the final fair value determination of the Acquisition in the fourth quarter of fiscal year 2022. The Company used variations of the income approach in determining the fair value of intangible assets acquired in the Acquisition. Specifically, the Company utilized the multi-period excess earnings method to determine the fair value of the definite lived customer relationships acquired and the relief from royalty method to determine the fair value of the definite lived trade name acquired. The Company’s determination of the fair value of the intangible assets acquired involved the use of significant estimates and assumptions related to revenue growth rates, discount rates, customer attrition rates, and royalty rates. Edgewell believes that the fair value assigned to the assets acquired and liabilities assumed are based on reasonable assumptions and estimates that marketplace participants would use. The following table provides the allocation of the purchase price related to the Acquisition based upon the fair value of assets and liabilities assumed: Current assets $ 17.0 Goodwill 181.2 Intangible assets 136.0 Other assets, including property, plant and equipment, net 3.2 Current liabilities (6.9) Deferred tax liabilities (21.1) Cash consideration, net of cash acquired $ 309.4 The acquired goodwill represented the value of expansion into new categories, markets and channels of trade and is not deductible for tax purposes. The intangible assets acquired consisted primarily of the Billie trade name and customer relationships with a weighted average useful life of 19 years. All assets are included in the Company’s Wet Shave segment. The following summarizes the company's unaudited pro forma consolidated results of operations for the three and six months ended March 31, 2022, as though the Acquisition occurred on October 1, 2020. The three and six months ended March 31, 2023 include results of Billie over the full periods presented. Three Months Ended Six Months Ended Pro forma net sales $ 547.7 $ 1,021.0 Pro forma net earnings 23.9 38.7 The unaudited pro forma consolidated results of operations were adjusted by pre-tax amortization expense of $1.3 for the six months ended March 31, 2022. Additionally, pro forma earnings for the three and six months ended March 31, 2022 exclude $1.1 and $7.1 of pre-tax acquisition costs, respectively, as these costs would have been incurred in the prior year. The pro forma earnings were also adjusted to reflect the capital structure as of the Acquisition Date, and all pro forma adjustments have been included with related tax effects. The unaudited pro forma consolidated results of operations is not necessarily indicative of the results obtained had the Acquisition occurred on October 1, 2020, or of those results that may be obtained in the future. Amounts do not reflect any anticipated cost savings or cross-selling opportunities expected to result from the Acquisition. |
Restructuring Charges
Restructuring Charges | 6 Months Ended |
Mar. 31, 2023 | |
Restructuring Charges [Abstract] | |
Restructuring Charges | Restructuring Charges Operating Model Redesign In fiscal 2023, the Company is continuing to take actions to strengthen its operating model, simplify the organization and improve manufacturing and supply chain efficiency and productivity. As a result of these actions, the Company expects to incur restructuring charges of approximately $19 in fiscal 2023. The Company incurred restructuring charges as follows: Three Months Ended Three Months Ended Six Months Ended Six Months Ended Severance and related benefit costs $ 1.9 $ 1.7 $ 2.8 $ 3.0 Asset write-off and accelerated depreciation 0.2 0.1 0.2 0.1 Consulting, project implementation and management, and other exit costs 1.1 1.9 3.0 2.8 Total restructuring (1)(2) $ 3.2 $ 3.7 $ 6.0 $ 5.9 (1) Restructuring costs of $0.2 are included within Cost of products sold for both the three and six months ended March 31, 2023. (2) Restructuring costs of $0.1 are included within Selling, general and administrative expense (“SG&A”) for the six months ended March 31, 2023, and $0.2 for both the three and six months ended March 31, 2022. The following table summarizes the restructuring activities and related accrual for the six months ended March 31, 2023: Utilized October 1, 2022 Charge to Cash March 31, Severance and related benefit costs $ 1.7 $ 2.8 $ (2.9) $ 1.6 Asset write-off and accelerated depreciation — 0.2 (0.2) — Consulting, project implementation and management, and other exit costs 0.8 3.0 (3.7) 0.1 Total restructuring activities and related accrual $ 2.5 $ 6.0 $ (6.8) $ 1.7 |
Earnings per Share
Earnings per Share | 6 Months Ended |
Mar. 31, 2023 | |
Earnings Per Share [Abstract] | |
Earnings per Share | Earnings per Share Basic earnings per share is based on the weighted-average number of common shares outstanding during the period. Diluted earnings per share is based on the number of shares used for the basic earnings per share calculation, adjusted for the dilutive effect of share options, restricted share equivalent (“RSE”) and performance restricted share equivalent (“PRSE”) awards. The following is the reconciliation between the number of weighted-average shares used in the basic and diluted earnings per share calculation: Three Months Ended Six Months Ended 2023 2022 2023 2022 Basic weighted-average shares outstanding 51.4 53.6 51.5 54.0 Effect of dilutive securities: Options, RSE and PRSE awards 0.6 0.7 0.5 0.6 Total dilutive securities 0.6 0.7 0.5 0.6 Diluted weighted-average shares outstanding 52.0 54.3 52.0 54.6 For the three and six months ended March 31, 2023, the calculation of diluted weighted-average shares outstanding excludes 0.8 and 1.0, respectively, of share options and nil and 0.2, respectively, of RSE and PRSE awards because the effect of including these awards was anti-dilutive. For the three and six months ended March 31, 2022, the calculation of diluted weighted-average shares outstanding excludes 1.2 of share options for both periods and 0.1 and 0.4, respectively, of RSE and PRSE awards because the effect of including these awards was anti-dilutive. |
Goodwill and Intangible Assets
Goodwill and Intangible Assets | 3 Months Ended |
Mar. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill and Intangible Assets | Goodwill and Intangible Assets The following table sets forth goodwill by segment: Wet Sun and Skin Feminine Total Gross balance as of October 1, 2022 $ 1,133.5 $ 354.5 $ 205.2 $ 1,693.2 Accumulated goodwill impairment (369.0) (2.0) — (371.0) Net balance as of October 1, 2022 $ 764.5 $ 352.5 $ 205.2 $ 1,322.2 Changes in the six months ended March 31, 2023 Cumulative translation adjustment 9.0 1.5 0.9 11.4 Gross balance as of March 31, 2023 $ 1,142.5 $ 356.0 $ 206.1 $ 1,704.6 Accumulated goodwill impairment (369.0) (2.0) — (371.0) Net balance as of March 31, 2023 $ 773.5 $ 354.0 $ 206.1 $ 1,333.6 The following table sets forth intangible assets by class: March 31, 2023 September 30, 2022 Carrying Accumulated Net Carrying Accumulated Net Indefinite lived Trade names and brands $ 594.6 $ — $ 594.6 $ 587.1 $ — $ 587.1 Amortizable Trade names and brands $ 339.7 $ 80.4 $ 259.3 $ 339.4 $ 72.2 $ 267.2 Technology and patents 78.5 76.0 2.5 77.8 75.0 2.8 Customer related and other 268.1 134.4 133.7 267.1 127.5 139.6 Amortizable intangible assets 686.3 290.8 395.5 684.3 274.7 409.5 Total intangible assets $ 1,280.9 $ 290.8 $ 990.1 $ 1,271.4 $ 274.7 $ 996.6 Amortization expense was $7.7 and $15.4 for the three and six months ended March 31, 2023, respectively, and $7.9 and $14.0 for the three and six months ended March 31, 2022, respectively. Estimated amortization expense for amortizable intangible assets for the remainder of fiscal 2023 and for fiscal 2024, 2025, 2026, 2027 and 2028 is $15.4, $30.7, $30.7, $30.5, $30.4 and $30.3, respectively, and $227.5 thereafter. Goodwill and intangible assets deemed to have an indefinite life are not amortized but are instead reviewed annually for impairment or when indicators of a potential impairment are present. The Company’s annual impairment testing date is July 1. An interim impairment analysis may indicate that carrying amounts of goodwill and other intangible assets require adjustment or that remaining useful lives should be revised. The Company determined there was no triggering event requiring an interim impairment analysis during the six months ended March 31, 2023. |
Supplemental Balance Sheet Info
Supplemental Balance Sheet Information | 6 Months Ended |
Mar. 31, 2023 | |
Supplemental Balance Sheet Information [Abstract] | |
Supplemental Balance Sheet Information | Supplemental Balance Sheet Information March 31, September 30, Inventories Raw materials and supplies $ 95.3 $ 80.4 Work in process 99.1 103.2 Finished products 346.1 265.7 Total inventories $ 540.5 $ 449.3 Other Current Assets Prepaid expenses 75.1 70.2 Value added tax receivables 42.4 52.7 Income taxes receivable 20.0 19.3 Other 15.2 25.1 Total other current assets $ 152.7 $ 167.3 Property, Plant and Equipment Land $ 18.7 $ 18.0 Buildings 143.3 140.3 Machinery and equipment 1,093.5 1,050.0 Capitalized software costs 59.5 56.5 Construction in progress 38.9 47.0 Total gross property, plant and equipment 1,353.9 1,311.8 Accumulated depreciation and amortization (1,011.6) (966.3) Total property, plant and equipment, net $ 342.3 $ 345.5 Other Current Liabilities Accrued advertising and sales promotion $ 44.8 $ 34.9 Other 257.6 256.8 Total other current liabilities $ 302.4 $ 291.7 Other Liabilities Pensions and other retirement benefits $ 58.3 $ 57.9 Other 109.1 115.7 Total other liabilities $ 167.4 $ 173.6 |
Leases
Leases | 6 Months Ended |
Mar. 31, 2023 | |
Leases [Abstract] | |
Leases | Leases The Company leases certain offices and manufacturing facilities, warehouses, employee vehicles and certain manufacturing related equipment and determines if an arrangement is or contains a lease at inception. Leases may include options to extend or terminate the lease, and those options are recorded on the Condensed Consolidated Balance Sheet when it is reasonably certain that the Company will exercise one of those options. All recorded leases are classified as operating leases, and lease expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheet. A summary of the Company's lease information is as follows: March 31, September 30, Assets Classification Right of use assets Other assets $ 49.6 $ 50.1 Liabilities Current lease liabilities Other current liabilities $ 9.0 $ 8.8 Long-term lease liabilities Other liabilities 41.0 41.5 Total lease liabilities $ 50.0 $ 50.3 Other information Weighted-average remaining lease term (years) 10 10 Weighted-average incremental borrowing rate 6.7 % 6.6 % Three Months Ended Six Months Ended 2023 2022 2023 2022 Statement of Earnings Lease expense (1) $ 3.1 $ 3.3 $ 6.1 $ 6.8 Other information Leased assets obtained in exchange for new lease liabilities $ 0.5 $ 2.4 $ 1.5 $ 2.9 Cash paid for amounts included in the measurement of lease liabilities $ 3.0 $ 3.3 $ 6.0 $ 6.9 (1) Lease expense is included in Cost of products sold or SG&A expense based on the nature of the lease. Short-term lease expense is not considered material and is, therefore, excluded from this amount. The Company's future lease payments, including reasonably assured renewal options under leases, are as follows: Lease liability repayments March 31, 2023 Remainder of fiscal 2023 $ 5.6 2024 10.1 2025 9.1 2026 7.6 2027 5.8 2028 and thereafter 36.8 Total future minimum lease commitments 75.0 Less: Imputed interest (25.0) Present value of lease liabilities $ 50.0 |
Accounts Receivable Facility
Accounts Receivable Facility | 6 Months Ended |
Mar. 31, 2023 | |
Transfers and Servicing [Abstract] | |
Accounts receivable facility | Accounts Receivable Facilities The Company participates in accounts receivable facility programs both in the United States and Japan. These receivable agreements are between the Company and MUFG Bank, LTD, and the subsidiaries of both parties. Transfers under the accounts receivable repurchase agreements are accounted for as sales of accounts receivables, resulting in the receivables being derecognized from the Condensed Consolidated Balance Sheet. The purchaser assumes the credit risk at the time of sale and has the right at any time to assign, transfer, or participate any of its rights under the purchased receivables to another bank or financial institution. The purchase and sale of receivables under accounts receivable repurchase agreements is intended to be an absolute and irrevocable transfer without recourse by the purchaser to the Company for the creditworthiness of any obligor. The Company has considered its performance obligation to collect and service the receivables sold in the United States and Japan and has determined that such services are not material. The compensation received is considered acceptable servicing compensation and as such, the Company does not recognize a servicing asset or liability. Accounts receivables sold were $315.5 and $527.6 for the three and six months ended March 31, 2023, respectively, and $282.0 and $437.2 for the three and six months ended March 31, 2022, respectively. The trade receivables sold that remained outstanding as of March 31, 2023 and September 30, 2022 were $141.1 and $78.7, respectively. The net proceeds received were included in both Cash used by operating activities and Cash used by investing activities on the Condensed Consolidated Statements of Cash Flows. The difference between the carrying amount of the trade receivables sold and the sum of the cash received is recorded as a loss on sale of receivables in Other expense (income), net in the Condensed Consolidated Statements of Earnings and Comprehensive Income. The loss on sale of trade receivables was $1.5 and $2.4 for the three and six months ended March 31, 2023, respectively, and $0.3 and $0.5 for the three and six months ended March 31, 2022, respectively. |
Debt
Debt | 6 Months Ended |
Mar. 31, 2023 | |
Debt Disclosure [Abstract] | |
Debt | Debt The detail of long-term debt was as follows: March 31, September 30, Senior notes, fixed interest rate of 5.500%, due 2028 $ 750.0 $ 750.0 Senior notes, fixed interest rate of 4.125%, due 2029 500.0 500.0 U.S. revolving credit facility (1) 176.0 155.0 Total long-term debt 1,426.0 1,405.0 Less unamortized debt issuance costs and discount (2) 12.4 13.6 Total long-term debt $ 1,413.6 $ 1,391.4 (1) The U.S. revolving credit facility matures in April 2025. (2) As of March 31, 2023, the balance for the Senior Notes due 2028 and the Senior Notes due 2029 are reflected net of debt issuance costs of $7.6 and $4.8, respectively. As of September 30, 2022, the balance for the Senior Notes due 2028 and the Senior Notes due 2029 are reflected net of debt issuance costs of $8.3 and $5.3, respectively. |
Retirement Plans
Retirement Plans | 6 Months Ended |
Mar. 31, 2023 | |
Retirement Benefits [Abstract] | |
Retirement Plans | Retirement PlansThe Company has several defined benefit pension plans covering employees in the U.S. and certain employees in other countries. The plans provide retirement benefits based on years of service and compensation. The Company also sponsors or participates in several other non-U.S. pension and postretirement arrangements, including various retirement and termination benefit plans, some of which are required by local law or coordinated with government-sponsored plans, which are not significant in the aggregate and, therefore, are not included in the information presented below. The Company’s net periodic pension and postretirement costs (income) for its material plans were as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Service cost $ 0.4 $ 1.0 $ 0.9 $ 2.0 Interest cost 5.4 2.6 10.6 5.2 Expected return on plan assets (5.5) (5.3) (10.9) (10.6) Recognized net actuarial loss 0.4 1.6 0.8 3.1 Defined benefit settlement loss 7.2 — 7.2 — Net periodic cost (income) $ 7.9 $ (0.1) $ 8.6 $ (0.3) The service cost component of the net periodic cost (income) associated with the Company’s retirement plans is recorded to Cost of products sold and SG&A on the Condensed Consolidated Statement of Earnings and Comprehensive Income. The remaining net periodic cost (income) is recorded to Other expense (income), net on the Condensed Consolidated Statement of Earnings and Comprehensive Income. The Company initiated the wind-up of its Canadian defined benefit pension plan (“Canada Plan”) in June 2021. On September 1, 2021, Edgewell Personal Care Canada ULC (“EPC Canada”) as administrator of the Canada Plan entered into a buy-in annuity purchase agreement (“Buy-in Agreement”) with Brookfield Annuity Company (“Brookfield Annuity”) for certain members of the Canada Plan. On January 25, 2023, the Company received approval by the Financial Services Regulatory Authority of Ontario to wind-up the Canada Plan. Upon regulatory approval of the Canada Plan, EPC Canada proceeded with purchasing annuities for the remaining Canada Plan participants and converting the Buy-in Agreement to a buy-out annuity purchase agreement (“Buy-out Agreement”), which was purchased and funded by the Canada Plan on March 31, 2023. The Company was relieved of its defined benefit pension obligation through its irrevocable commitment under the Buy-out Agreement. As of the settlement date, the Company remeasured its assets and its project benefit obligation associated with the Canada Plan. Upon settlement, the Company derecognized the assets, projected benefit obligation and losses remaining in accumulated other comprehensive loss associated with the Canada Plan, which resulted in a loss on settlement of $7.2. The loss was recorded in Other expense (income), net on the Condensed Consolidated Statement of Earnings and Comprehensive Income for the three and six months ended March 31, 2023. |
Equity
Equity | 6 Months Ended |
Mar. 31, 2023 | |
Equity [Abstract] | |
Shareholders' Equity | Shareholders’ Equity Share Repurchases In January 2018, the Company’s Board of Directors (the “Board”) authorized the repurchase of up to 10.0 shares of the Company’s common stock, replacing the previous share repurchase authorization from May 2015. The Company repurchased 0.8 shares of its common stock for $30.0 during the six months ended March 31, 2023. There are 5.7 shares of common stock available for repurchase in the future under the Board’s authorization as of March 31, 2023. Any future share repurchases may be made in the open market, privately negotiated transactions, or otherwise permitted, and in such amounts and at such times as the Company deems appropriate based upon prevailing market conditions, business needs, and other factors. Dividends On November 3, 2022, the Board declared a quarterly cash dividend of $0.15 per common share for the fourth fiscal quarter of 2022. The dividend was paid on January 4, 2023 to shareholders of record as of the close of business on November 29, 2022. On February 3, 2023, the Board declared a quarterly cash dividend of $0.15 per common share for the first fiscal quarter of 2023. The dividend was paid on April 5, 2023 to stockholders of record as of the close of business on March 8, 2023. |
Accumulated Other Comprehensive
Accumulated Other Comprehensive Loss | 6 Months Ended |
Mar. 31, 2023 | |
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] | |
Accumulated Other Comprehensive Loss | Accumulated Other Comprehensive Loss The following table presents the changes in accumulated other comprehensive loss (“AOCI”), net of tax, by component: Foreign Pension and Hedging Total Balance as of October 1, 2022 $ (131.2) $ (92.6) $ 7.7 $ (216.1) OCI before reclassifications (1) 60.1 (1.6) (4.0) 54.5 Reclassifications to earnings — 5.9 (4.0) 1.9 Balance as of March 31, 2023 $ (71.1) $ (88.3) $ (0.3) $ (159.7) Foreign Pension and Hedging Total Balance as of October 1, 2021 $ (41.8) $ (97.3) $ 2.2 $ (136.9) OCI before reclassifications (1) (15.9) (2.2) 3.3 (14.8) Reclassifications to earnings — 2.3 (1.9) 0.4 Balance as of March 31, 2022 $ (57.7) $ (97.2) $ 3.6 $ (151.3) (1) OCI is defined as other comprehensive income (loss). The following table presents the reclassifications out of AOCI: Three Months Ended Six Months Ended Affected Line Item in the Details of AOCI Components 2023 2022 2023 2022 Gain / (Loss) on cash flow hedges Foreign exchange contracts $ 0.8 $ 1.6 $ 5.8 $ 2.9 Other expense (income), net Income tax expense (benefit) 0.2 0.5 1.8 1.0 Income tax provision 0.6 1.1 4.0 1.9 Amortization of defined benefit pension and postretirement items Actuarial losses (1) $ (0.4) $ (1.6) $ (0.8) $ (3.1) Defined benefit settlement loss (7.2) — (7.2) — Other expense (income), net Income tax expense (benefit) (2.0) (0.4) (2.1) (0.8) Income tax provision (5.6) (1.2) (5.9) (2.3) Total reclassifications for the period $ (5.0) $ (0.1) $ (1.9) $ (0.4) (1) These AOCI components are included in the computation of net periodic cost. See Note 11 of Notes to Condensed Consolidated Financial Statements. |
Financial Instruments and Risk
Financial Instruments and Risk Management | 6 Months Ended |
Mar. 31, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Financial Instruments and Risk Management | Financial Instruments and Risk Management In the ordinary course of business, the Company may enter into contractual arrangements (also referred to as derivatives) to reduce its exposure to foreign currency. The Company has master netting agreements with all of its counterparties that allow for the settlement of contracts in an asset position with contracts in a liability position in the event of default. The Company manages counterparty risk through the utilization of investment grade commercial banks, diversification of counterparties, and its counterparty netting arrangements. The section below outlines the types of derivatives in place as of March 31, 2023 and September 30, 2022, as well as the Company’s objectives and strategies for holding derivative instruments. Foreign Currency Risk A significant share of the Company’s sales is tied to currencies other than the U.S. dollar, the Company’s reporting currency. As such, a weakening of currencies relative to the U.S. dollar can have a unfavorable impact on reported earnings. Conversely, strengthening of currencies relative to the U.S. dollar can improve reported results. The primary currencies to which the Company is exposed include the euro, the Japanese yen, the British pound, the Canadian dollar, and the Australian dollar. Additionally, the Company’s foreign subsidiaries enter into internal and external transactions that create non-functional currency balance sheet positions at the foreign subsidiary level. These exposures are generally the result of intercompany purchases, intercompany loans and, to a lesser extent, external purchases, and are revalued in the foreign subsidiary’s local currency at the end of each month. Changes in the value of the non-functional currency balance sheet positions in relation to the foreign subsidiary’s local currency results in an exchange gain or loss recorded in Other expense (income), net. The primary currency to which the Company’s foreign subsidiaries are exposed is the U.S. dollar. Cash Flow Hedges As of March 31, 2023, the Company maintained a cash flow hedging program related to foreign currency risk. These derivative instruments have a high correlation to the underlying exposure being hedged and have been deemed highly effective by the Company for accounting purposes in offsetting the associated risk. The Company has forward currency contracts to hedge cash flow uncertainty associated with currency fluctuations. These transactions are accounted for as cash flow hedges. The Company had unrealized pre-tax losses of $0.3 and gains of $11.3 as of March 31, 2023 and September 30, 2022, respectively, on these forward currency contracts, which are accounted for as cash flow hedges and included in AOCI. Assuming foreign exchange rates versus the U.S. dollar remain at March 31, 2023 levels over the next 12 months, the majority of the pre-tax loss included in AOCI as of March 31, 2023 is expected to be included in Other expense (income), net. Contract maturities for these hedges extend into fiscal 2024. As of March 31, 2023, there were 64 open foreign currency contracts with a total notional value of $114.1. Derivatives not Designated as Hedges The Company has foreign currency derivative contracts, which are not designated as cash flow hedges for accounting purposes, to hedge balance sheet exposures. Any gains or losses on these contracts are expected to be offset by exchange gains or losses on the underlying exposures and, thus, are not expected to be subject to significant market risk. The change in the estimated fair value of the foreign currency contracts for the three and six months ended March 31, 2023, resulted in a gain of $ 2.4 (0.3) 0.6 1.7 The following table provides estimated fair values of derivative instruments: Fair Value of Assets (Liabilities) as of (1) March 31, September 30, Derivatives designated as cash flow hedging relationships: Foreign currency contracts $ (0.3) $ 11.3 Derivatives not designated as cash flow hedging relationships: Foreign currency contracts $ (0.3) $ 2.0 (1) Derivative assets are presented in Other current assets or Other assets. Derivative liabilities are presented in Other current liabilities or Other liabilities. The following table provides the pre-tax amounts of gains and losses on derivative instruments: Three Months Ended Six Months Ended 2023 2022 2023 2022 Derivatives designated as cash flow hedging relationships: Foreign currency contracts Gain (loss) recognized in OCI (1) $ 1.3 $ 3.1 $ (5.8) $ 4.9 Gain reclassified from AOCI into income (1) (2) 0.9 1.6 5.8 2.9 Derivatives not designated as cash flow hedging relationships: Foreign currency contracts Gain (loss) recognized in income (2) $ 2.4 $ 0.6 $ (0.3) $ 1.7 (1) Each of these derivative instruments had a high correlation to the underlying exposure being hedged for the periods indicated and have been deemed highly effective by the Company in offsetting associated risk. (2) Gain was recorded in Other expense (income), net. The following table provides financial assets and liabilities for balance sheet offsetting: As of March 31, 2023 As of September 30, 2022 Assets (1) Liabilities (2) Assets (1) Liabilities (2) Foreign currency contracts Gross amounts of recognized assets (liabilities) $ 1.8 $ (3.0) $ 13.4 $ (0.5) Gross amounts offset in the balance sheet (0.1) 0.7 — 0.4 Net amounts of assets (liabilities) presented in the balance sheet $ 1.7 $ (2.3) $ 13.4 $ (0.1) (1) All derivative assets are presented in Other current assets or Other assets. (2) All derivative liabilities are presented in Other current liabilities or Other liabilities. Fair Value Hierarchy Accounting guidance on fair value measurements for certain financial assets and liabilities requires that assets and liabilities carried at fair value be classified in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions or external inputs from inactive markets. The following table sets forth the Company’s financial assets and liabilities, which are carried at fair value and measured on a recurring basis during the period, all of which are classified as Level 2 within the fair value hierarchy: March 31, September 30, Assets (Liabilities) at estimated fair value: Deferred compensation liability $ (19.0) $ (21.8) Derivatives - foreign currency contracts (liability) asset (0.6) 13.3 Net liabilities at estimated fair value $ (19.6) $ (8.5) The estimated fair value of the deferred compensation liability is determined based upon the quoted market prices of the investment options that are offered under the plan. As of March 31, 2023 and September 30, 2022, the estimated fair value of foreign currency contracts is the amount that the Company would receive or pay to terminate the contracts, considering first the quoted market prices of comparable agreements or, in the absence of quoted market prices, factors such as interest rates, currency exchange rates, and remaining maturities. As of March 31, 2023 and September 30, 2022, the Company had no Level 1 financial assets or liabilities, other than pension plan assets, and no Level 3 financial assets or liabilities as of March 31, 2023 and September 30, 2022, respectively. |
Segment Data
Segment Data | 6 Months Ended |
Mar. 31, 2023 | |
Segment Reporting [Abstract] | |
Segment Data | Segment Data For an overview of the Company’s segments, refer to Note 1 of the Notes to Condensed Consolidated Financial Statements. Segment performance is evaluated based on segment profit, excluding certain U.S. GAAP items that management does not believe are indicative of ongoing operating performance. These items include general corporate expenses, share-based compensation costs, amortization of intangible assets and certain other items, including restructuring charges, acquisition and integration costs, Sun Care reformulation costs, value-added tax settlement costs, loss on defined benefit settlement and at times management excludes other costs. Financial items, such as interest income and expense, are managed on a global basis at the corporate level and therefore are excluded from segment profit. The exclusion of such charges from segment results reflects management’s view on how management monitors and evaluates segment operating performance, generates future operating plans and makes strategic decisions regarding the allocation of capital. The Company’s operating model includes some shared business functions across the segments, including product warehousing and distribution, transaction processing functions and, in most cases, combined sales force and management teams. The Company applies a fully allocated cost basis in which shared business functions are allocated between the segments. Segment net sales and profitability are presented below: Three Months Ended Six Months Ended 2023 2022 2023 2022 Net Sales Wet Shave $ 308.6 $ 305.0 $ 583.9 $ 591.1 Sun and Skin Care 209.7 183.3 322.6 288.1 Feminine Care 80.1 59.4 161.0 131.8 Total net sales $ 598.4 $ 547.7 $ 1,067.5 $ 1,011.0 Segment Profit Wet Shave $ 35.1 $ 27.6 $ 70.5 $ 79.1 Sun and Skin Care 39.9 42.3 53.0 46.0 Feminine Care 12.0 1.9 23.8 10.3 Total segment profit 87.0 71.8 147.3 135.4 General corporate and other expenses (17.0) (17.2) (32.9) (28.0) Amortization of intangibles (7.7) (7.9) (15.4) (14.0) Interest and other expense, net (23.0) (14.6) (37.9) (30.2) Restructuring and related costs (1) (3.0) (3.7) (5.8) (5.9) Acquisition and integration costs (2) (2.0) (1.1) (4.1) (7.1) Sun Care reformulation costs (3) (0.6) (0.2) (1.1) (3.5) Defined benefit settlement loss (4) (7.2) — (7.2) — VAT settlement costs (5) — — — (3.4) Other costs (0.5) — (0.5) — Total earnings before income taxes $ 26.0 $ 27.1 $ 42.4 $ 43.3 (1) Restructuring costs of $0.2 are included within Cost of products sold for the three and six months ended March 31, 2023. Includes pre-tax SG&A of $0.1 for the six months ended March 31, 2023 and $0.2 for both the three and six months ended March 31, 2022. (2) Includes pre-tax SG&A of $0.6 and $6.3 for the three and six months ended March 31, 2022, respectively, for the Acquisition. Additionally, includes Cost of Products Sold of $0.5 and $0.8 related to the valuation of acquired inventory for the Acquisition for the three and six months ended March 31, 2022, respectively. See Note 2 of the Notes to Condensed Consolidated Financial Statements. (3) Includes pre-tax R&D of $0.6 and $1.1 for the three and six months ended March 31, 2023, respectively, and pre-tax Cost of Products Sold of $0.2 and $3.5 for the three and six months ended March 31, 2022, respectively, related to the reformulation, recall and destruction of certain Sun Care products. (4) Includes pre-tax loss of $7.2 for the three and six months ended March 31, 2023 related the settlement of the Canada Plan. See Note 11 of the Notes to Condensed Consolidated Financial Statements. (5) Includes pre-tax SG&A of $3.4 for the six months ended March 31, 2022 related to the estimated settlement of a prior years’ value-added tax audit of the Company’s German subsidiary. The following table presents the Company’s net sales by geographic area: Three Months Ended Six Months Ended 2023 2022 2023 2022 Net Sales to Customers United States $ 367.9 $ 341.9 $ 639.7 $ 604.4 International 230.5 205.8 427.8 406.6 Total net sales $ 598.4 $ 547.7 $ 1,067.5 $ 1,011.0 Supplemental product information is presented below for net sales: Three Months Ended Six Months Ended 2023 2022 2023 2022 Razors and blades $ 278.4 $ 275.3 $ 525.4 $ 531.0 Tampons, pads, and liners 80.1 59.4 161.0 131.8 Sun care products 153.8 131.4 201.6 171.6 Grooming products 38.0 34.4 85.3 80.7 Wipes and other skin care 17.9 17.5 35.7 35.8 Shaving gels and creams 30.2 29.7 58.5 60.1 Total net sales $ 598.4 $ 547.7 $ 1,067.5 $ 1,011.0 |
Organization, Consolidation and
Organization, Consolidation and Presentation of Financial Statements (Policies) | 6 Months Ended |
Mar. 31, 2023 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Business Description and Basis of Presentation | Edgewell Personal Care Company and its subsidiaries (collectively, “Edgewell” or the “Company”) is one of the world’s largest manufacturers and marketers of personal care products in the wet shave, sun and skin care, and feminine care categories. With operations in over 20 countries and with products widely available in more than 50 countries. The Company conducts its business in the following three segments: • Wet Shave consists of products sold under the Schick®, Wilkinson Sword®, Edge, Skintimate®, Billie®, Shave Guard and Personna® brands, as well as non-branded products. The Company’s wet shave products include razor handles and refillable blades, disposable shave products, and shaving gels and creams. • Sun and Skin Care consists of Banana Boat® and Hawaiian Tropic® sun care products, Jack Black®, Bulldog® and Cremo® men’s grooming products, Billie women’s grooming products and Wet Ones® products. • Feminine Care includes tampons, pads, and liners sold under the Playtex Gentle Glide® and Sport®, Stayfree®, Carefree®, and o.b.® brands. |
Basis of Accounting, Policy | Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its controlled subsidiaries and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“GAAP”) under the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”). The preparation of the unaudited Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results may differ materially from those estimates. All intercompany balances and transactions have been eliminated in consolidation and, in the opinion of management, all normal recurring adjustments considered necessary for a fair statement have been included in the interim results reported. The fiscal year-end balance sheet data was derived from audited consolidated financial statements, but do not include all of the annual disclosures required by GAAP; accordingly, these unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company’s audited annual consolidated financial statements included in its Annual Report on Form 10-K filed with the SEC on November 16, 2022. |
Business Combinations (Tables)
Business Combinations (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Business Combinations [Abstract] | |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | The following table provides the allocation of the purchase price related to the Acquisition based upon the fair value of assets and liabilities assumed: Current assets $ 17.0 Goodwill 181.2 Intangible assets 136.0 Other assets, including property, plant and equipment, net 3.2 Current liabilities (6.9) Deferred tax liabilities (21.1) Cash consideration, net of cash acquired $ 309.4 |
Restructuring Charges (Tables)
Restructuring Charges (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Restructuring Charges [Abstract] | |
Schedule of Charges Related to Restructuring Activities | Three Months Ended Three Months Ended Six Months Ended Six Months Ended Severance and related benefit costs $ 1.9 $ 1.7 $ 2.8 $ 3.0 Asset write-off and accelerated depreciation 0.2 0.1 0.2 0.1 Consulting, project implementation and management, and other exit costs 1.1 1.9 3.0 2.8 Total restructuring (1)(2) $ 3.2 $ 3.7 $ 6.0 $ 5.9 (1) Restructuring costs of $0.2 are included within Cost of products sold for both the three and six months ended March 31, 2023. (2) Restructuring costs of $0.1 are included within Selling, general and administrative expense (“SG&A”) for the six months ended March 31, 2023, and $0.2 for both the three and six months ended March 31, 2022. |
Schedule of Restructuring Activities and Related Accruals | The following table summarizes the restructuring activities and related accrual for the six months ended March 31, 2023: Utilized October 1, 2022 Charge to Cash March 31, Severance and related benefit costs $ 1.7 $ 2.8 $ (2.9) $ 1.6 Asset write-off and accelerated depreciation — 0.2 (0.2) — Consulting, project implementation and management, and other exit costs 0.8 3.0 (3.7) 0.1 Total restructuring activities and related accrual $ 2.5 $ 6.0 $ (6.8) $ 1.7 |
Earnings per Share (Tables)
Earnings per Share (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Earnings Per Share [Abstract] | |
Schedule of Weighted-Average Shares Outstanding | The following is the reconciliation between the number of weighted-average shares used in the basic and diluted earnings per share calculation: Three Months Ended Six Months Ended 2023 2022 2023 2022 Basic weighted-average shares outstanding 51.4 53.6 51.5 54.0 Effect of dilutive securities: Options, RSE and PRSE awards 0.6 0.7 0.5 0.6 Total dilutive securities 0.6 0.7 0.5 0.6 Diluted weighted-average shares outstanding 52.0 54.3 52.0 54.6 |
Goodwill and Intangible Assets
Goodwill and Intangible Assets (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Goodwill | The following table sets forth goodwill by segment: Wet Sun and Skin Feminine Total Gross balance as of October 1, 2022 $ 1,133.5 $ 354.5 $ 205.2 $ 1,693.2 Accumulated goodwill impairment (369.0) (2.0) — (371.0) Net balance as of October 1, 2022 $ 764.5 $ 352.5 $ 205.2 $ 1,322.2 Changes in the six months ended March 31, 2023 Cumulative translation adjustment 9.0 1.5 0.9 11.4 Gross balance as of March 31, 2023 $ 1,142.5 $ 356.0 $ 206.1 $ 1,704.6 Accumulated goodwill impairment (369.0) (2.0) — (371.0) Net balance as of March 31, 2023 $ 773.5 $ 354.0 $ 206.1 $ 1,333.6 |
Schedule of Amortizable Intangible Assets | The following table sets forth intangible assets by class: March 31, 2023 September 30, 2022 Carrying Accumulated Net Carrying Accumulated Net Indefinite lived Trade names and brands $ 594.6 $ — $ 594.6 $ 587.1 $ — $ 587.1 Amortizable Trade names and brands $ 339.7 $ 80.4 $ 259.3 $ 339.4 $ 72.2 $ 267.2 Technology and patents 78.5 76.0 2.5 77.8 75.0 2.8 Customer related and other 268.1 134.4 133.7 267.1 127.5 139.6 Amortizable intangible assets 686.3 290.8 395.5 684.3 274.7 409.5 Total intangible assets $ 1,280.9 $ 290.8 $ 990.1 $ 1,271.4 $ 274.7 $ 996.6 |
Supplemental Balance Sheet In_2
Supplemental Balance Sheet Information (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Supplemental Balance Sheet Information [Abstract] | |
Supplement Balance Sheet Information | March 31, September 30, Inventories Raw materials and supplies $ 95.3 $ 80.4 Work in process 99.1 103.2 Finished products 346.1 265.7 Total inventories $ 540.5 $ 449.3 Other Current Assets Prepaid expenses 75.1 70.2 Value added tax receivables 42.4 52.7 Income taxes receivable 20.0 19.3 Other 15.2 25.1 Total other current assets $ 152.7 $ 167.3 Property, Plant and Equipment Land $ 18.7 $ 18.0 Buildings 143.3 140.3 Machinery and equipment 1,093.5 1,050.0 Capitalized software costs 59.5 56.5 Construction in progress 38.9 47.0 Total gross property, plant and equipment 1,353.9 1,311.8 Accumulated depreciation and amortization (1,011.6) (966.3) Total property, plant and equipment, net $ 342.3 $ 345.5 Other Current Liabilities Accrued advertising and sales promotion $ 44.8 $ 34.9 Other 257.6 256.8 Total other current liabilities $ 302.4 $ 291.7 Other Liabilities Pensions and other retirement benefits $ 58.3 $ 57.9 Other 109.1 115.7 Total other liabilities $ 167.4 $ 173.6 |
Leases (Tables)
Leases (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Leases [Abstract] | |
Summary of Lease Information | A summary of the Company's lease information is as follows: March 31, September 30, Assets Classification Right of use assets Other assets $ 49.6 $ 50.1 Liabilities Current lease liabilities Other current liabilities $ 9.0 $ 8.8 Long-term lease liabilities Other liabilities 41.0 41.5 Total lease liabilities $ 50.0 $ 50.3 Other information Weighted-average remaining lease term (years) 10 10 Weighted-average incremental borrowing rate 6.7 % 6.6 % Three Months Ended Six Months Ended 2023 2022 2023 2022 Statement of Earnings Lease expense (1) $ 3.1 $ 3.3 $ 6.1 $ 6.8 Other information Leased assets obtained in exchange for new lease liabilities $ 0.5 $ 2.4 $ 1.5 $ 2.9 Cash paid for amounts included in the measurement of lease liabilities $ 3.0 $ 3.3 $ 6.0 $ 6.9 |
Lessee, Operating Lease, Liability, Maturity | The Company's future lease payments, including reasonably assured renewal options under leases, are as follows: Lease liability repayments March 31, 2023 Remainder of fiscal 2023 $ 5.6 2024 10.1 2025 9.1 2026 7.6 2027 5.8 2028 and thereafter 36.8 Total future minimum lease commitments 75.0 Less: Imputed interest (25.0) Present value of lease liabilities $ 50.0 |
Debt (Tables)
Debt (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Debt Disclosure [Abstract] | |
Schedule of Long-term Debt | The detail of long-term debt was as follows: March 31, September 30, Senior notes, fixed interest rate of 5.500%, due 2028 $ 750.0 $ 750.0 Senior notes, fixed interest rate of 4.125%, due 2029 500.0 500.0 U.S. revolving credit facility (1) 176.0 155.0 Total long-term debt 1,426.0 1,405.0 Less unamortized debt issuance costs and discount (2) 12.4 13.6 Total long-term debt $ 1,413.6 $ 1,391.4 (1) The U.S. revolving credit facility matures in April 2025. (2) As of March 31, 2023, the balance for the Senior Notes due 2028 and the Senior Notes due 2029 are reflected net of debt issuance costs of $7.6 and $4.8, respectively. As of September 30, 2022, the balance for the Senior Notes due 2028 and the Senior Notes due 2029 are reflected net of debt issuance costs of $8.3 and $5.3, respectively. |
Retirement Plans (Tables)
Retirement Plans (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Retirement Benefits [Abstract] | |
Schedule of Net Periodic Pension and Postretirement Cost (Benefit) | The Company’s net periodic pension and postretirement costs (income) for its material plans were as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Service cost $ 0.4 $ 1.0 $ 0.9 $ 2.0 Interest cost 5.4 2.6 10.6 5.2 Expected return on plan assets (5.5) (5.3) (10.9) (10.6) Recognized net actuarial loss 0.4 1.6 0.8 3.1 Defined benefit settlement loss 7.2 — 7.2 — Net periodic cost (income) $ 7.9 $ (0.1) $ 8.6 $ (0.3) |
Accumulated Other Comprehensi_2
Accumulated Other Comprehensive Loss (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] | |
Schedule of Changes in Accumulated Other Comprehensive Loss | The following table presents the changes in accumulated other comprehensive loss (“AOCI”), net of tax, by component: Foreign Pension and Hedging Total Balance as of October 1, 2022 $ (131.2) $ (92.6) $ 7.7 $ (216.1) OCI before reclassifications (1) 60.1 (1.6) (4.0) 54.5 Reclassifications to earnings — 5.9 (4.0) 1.9 Balance as of March 31, 2023 $ (71.1) $ (88.3) $ (0.3) $ (159.7) Foreign Pension and Hedging Total Balance as of October 1, 2021 $ (41.8) $ (97.3) $ 2.2 $ (136.9) OCI before reclassifications (1) (15.9) (2.2) 3.3 (14.8) Reclassifications to earnings — 2.3 (1.9) 0.4 Balance as of March 31, 2022 $ (57.7) $ (97.2) $ 3.6 $ (151.3) (1) OCI is defined as other comprehensive income (loss). |
Schedule of Reclassifications out of Accumulated Other Comprehensive Loss | The following table presents the reclassifications out of AOCI: Three Months Ended Six Months Ended Affected Line Item in the Details of AOCI Components 2023 2022 2023 2022 Gain / (Loss) on cash flow hedges Foreign exchange contracts $ 0.8 $ 1.6 $ 5.8 $ 2.9 Other expense (income), net Income tax expense (benefit) 0.2 0.5 1.8 1.0 Income tax provision 0.6 1.1 4.0 1.9 Amortization of defined benefit pension and postretirement items Actuarial losses (1) $ (0.4) $ (1.6) $ (0.8) $ (3.1) Defined benefit settlement loss (7.2) — (7.2) — Other expense (income), net Income tax expense (benefit) (2.0) (0.4) (2.1) (0.8) Income tax provision (5.6) (1.2) (5.9) (2.3) Total reclassifications for the period $ (5.0) $ (0.1) $ (1.9) $ (0.4) (1) These AOCI components are included in the computation of net periodic cost. See Note 11 of Notes to Condensed Consolidated Financial Statements. |
Financial Instruments and Ris_2
Financial Instruments and Risk Management (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Fair Values of Derivative Instruments | The following table provides estimated fair values of derivative instruments: Fair Value of Assets (Liabilities) as of (1) March 31, September 30, Derivatives designated as cash flow hedging relationships: Foreign currency contracts $ (0.3) $ 11.3 Derivatives not designated as cash flow hedging relationships: Foreign currency contracts $ (0.3) $ 2.0 (1) Derivative assets are presented in Other current assets or Other assets. Derivative liabilities are presented in Other current liabilities or Other liabilities. |
Schedule of Gains and Losses on Derivative Instruments | The following table provides the pre-tax amounts of gains and losses on derivative instruments: Three Months Ended Six Months Ended 2023 2022 2023 2022 Derivatives designated as cash flow hedging relationships: Foreign currency contracts Gain (loss) recognized in OCI (1) $ 1.3 $ 3.1 $ (5.8) $ 4.9 Gain reclassified from AOCI into income (1) (2) 0.9 1.6 5.8 2.9 Derivatives not designated as cash flow hedging relationships: Foreign currency contracts Gain (loss) recognized in income (2) $ 2.4 $ 0.6 $ (0.3) $ 1.7 (1) Each of these derivative instruments had a high correlation to the underlying exposure being hedged for the periods indicated and have been deemed highly effective by the Company in offsetting associated risk. |
Schedule of Offsetting Assets and Liabilities | The following table provides financial assets and liabilities for balance sheet offsetting: As of March 31, 2023 As of September 30, 2022 Assets (1) Liabilities (2) Assets (1) Liabilities (2) Foreign currency contracts Gross amounts of recognized assets (liabilities) $ 1.8 $ (3.0) $ 13.4 $ (0.5) Gross amounts offset in the balance sheet (0.1) 0.7 — 0.4 Net amounts of assets (liabilities) presented in the balance sheet $ 1.7 $ (2.3) $ 13.4 $ (0.1) (1) All derivative assets are presented in Other current assets or Other assets. (2) All derivative liabilities are presented in Other current liabilities or Other liabilities. |
Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis | The following table sets forth the Company’s financial assets and liabilities, which are carried at fair value and measured on a recurring basis during the period, all of which are classified as Level 2 within the fair value hierarchy: March 31, September 30, Assets (Liabilities) at estimated fair value: Deferred compensation liability $ (19.0) $ (21.8) Derivatives - foreign currency contracts (liability) asset (0.6) 13.3 Net liabilities at estimated fair value $ (19.6) $ (8.5) |
Segment Data (Tables)
Segment Data (Tables) | 6 Months Ended |
Mar. 31, 2023 | |
Segment Reporting [Abstract] | |
Schedule of Segment Sales and Profitability | Segment net sales and profitability are presented below: Three Months Ended Six Months Ended 2023 2022 2023 2022 Net Sales Wet Shave $ 308.6 $ 305.0 $ 583.9 $ 591.1 Sun and Skin Care 209.7 183.3 322.6 288.1 Feminine Care 80.1 59.4 161.0 131.8 Total net sales $ 598.4 $ 547.7 $ 1,067.5 $ 1,011.0 Segment Profit Wet Shave $ 35.1 $ 27.6 $ 70.5 $ 79.1 Sun and Skin Care 39.9 42.3 53.0 46.0 Feminine Care 12.0 1.9 23.8 10.3 Total segment profit 87.0 71.8 147.3 135.4 General corporate and other expenses (17.0) (17.2) (32.9) (28.0) Amortization of intangibles (7.7) (7.9) (15.4) (14.0) Interest and other expense, net (23.0) (14.6) (37.9) (30.2) Restructuring and related costs (1) (3.0) (3.7) (5.8) (5.9) Acquisition and integration costs (2) (2.0) (1.1) (4.1) (7.1) Sun Care reformulation costs (3) (0.6) (0.2) (1.1) (3.5) Defined benefit settlement loss (4) (7.2) — (7.2) — VAT settlement costs (5) — — — (3.4) Other costs (0.5) — (0.5) — Total earnings before income taxes $ 26.0 $ 27.1 $ 42.4 $ 43.3 (1) Restructuring costs of $0.2 are included within Cost of products sold for the three and six months ended March 31, 2023. Includes pre-tax SG&A of $0.1 for the six months ended March 31, 2023 and $0.2 for both the three and six months ended March 31, 2022. (2) Includes pre-tax SG&A of $0.6 and $6.3 for the three and six months ended March 31, 2022, respectively, for the Acquisition. Additionally, includes Cost of Products Sold of $0.5 and $0.8 related to the valuation of acquired inventory for the Acquisition for the three and six months ended March 31, 2022, respectively. See Note 2 of the Notes to Condensed Consolidated Financial Statements. (3) Includes pre-tax R&D of $0.6 and $1.1 for the three and six months ended March 31, 2023, respectively, and pre-tax Cost of Products Sold of $0.2 and $3.5 for the three and six months ended March 31, 2022, respectively, related to the reformulation, recall and destruction of certain Sun Care products. (4) Includes pre-tax loss of $7.2 for the three and six months ended March 31, 2023 related the settlement of the Canada Plan. See Note 11 of the Notes to Condensed Consolidated Financial Statements. (5) Includes pre-tax SG&A of $3.4 for the six months ended March 31, 2022 related to the estimated settlement of a prior years’ value-added tax audit of the Company’s German subsidiary. |
Schedule of Sales by Geographic Area | The following table presents the Company’s net sales by geographic area: Three Months Ended Six Months Ended 2023 2022 2023 2022 Net Sales to Customers United States $ 367.9 $ 341.9 $ 639.7 $ 604.4 International 230.5 205.8 427.8 406.6 Total net sales $ 598.4 $ 547.7 $ 1,067.5 $ 1,011.0 |
Schedule of Supplemental Product Information | Supplemental product information is presented below for net sales: Three Months Ended Six Months Ended 2023 2022 2023 2022 Razors and blades $ 278.4 $ 275.3 $ 525.4 $ 531.0 Tampons, pads, and liners 80.1 59.4 161.0 131.8 Sun care products 153.8 131.4 201.6 171.6 Grooming products 38.0 34.4 85.3 80.7 Wipes and other skin care 17.9 17.5 35.7 35.8 Shaving gels and creams 30.2 29.7 58.5 60.1 Total net sales $ 598.4 $ 547.7 $ 1,067.5 $ 1,011.0 |
Background and Basis of Prese_2
Background and Basis of Presentation (Details) $ in Millions | 6 Months Ended | |
Mar. 31, 2023 USD ($) country | Mar. 31, 2022 USD ($) | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Number of countries in which Edgewell operates | 20 | |
Number of countries with retail operations | 50 | |
Repayments of Revolving Credit Facility | $ | $ 392 | $ 220 |
Business Combinations (Schedule
Business Combinations (Schedule of Recognized Identified Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 | Nov. 29, 2021 |
Business Acquisition [Line Items] | |||
Goodwill acquired | $ 1,333.6 | $ 1,322.2 | |
Billie | |||
Business Acquisition [Line Items] | |||
Current assets acquired | $ 17 | ||
Goodwill acquired | 181.2 | ||
Business combinations, intangible assets acquired | 136 | ||
Property, plant and equipment acquired | 3.2 | ||
Current liabilities assumed | (6.9) | ||
Deferred tax liabilities acquired | (21.1) | ||
Business combinations, assets acquired, goodwill and liabilities assumed, net | $ 309.4 |
Business Combinations (Details)
Business Combinations (Details) - USD ($) $ in Millions | 6 Months Ended | ||
Nov. 29, 2021 | Mar. 31, 2023 | Mar. 31, 2022 | |
Business Acquisition [Line Items] | |||
Acquisition of Billie, net of cash acquired | $ 309.4 | $ 0 | $ 309.4 |
Billie | |||
Business Acquisition [Line Items] | |||
Weighted average useful life of acquired intangible assets | 19 years |
Business Combinations (Detail_2
Business Combinations (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended |
Mar. 31, 2022 | Mar. 31, 2022 | |
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items] | ||
Proforma net sales | $ 547.7 | $ 1,021 |
Proforma net earnings | $ 23.9 | $ 38.7 |
Restructuring Charges (Schedule
Restructuring Charges (Schedule of Charges Related to Restructuring Activities) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | Sep. 30, 2022 | |
Restructuring Cost and Reserve [Line Items] | |||||
Severance Costs | $ 1.9 | $ 1.7 | $ 2.8 | $ 3 | |
Other Restructuring Costs | 1.1 | 1.9 | 3 | 2.8 | |
Restructuring and related costs | 3.2 | $ 3.7 | 6 | 5.9 | |
Restructuring Reserve | 1.7 | 1.7 | $ 2.5 | ||
Asset Impairment and Accelerated Depreciation | 0.2 | $ 0.1 | |||
Asset Impairment and Accelerated Depreciation [Member] | |||||
Restructuring Cost and Reserve [Line Items] | |||||
Restructuring and related costs | 0.2 | ||||
Restructuring Reserve | $ 0 | $ 0 | $ 0 |
Restructuring Charges (Schedu_2
Restructuring Charges (Schedule of Restructuring Activities and Related Accruals) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Restructuring Reserve [Roll Forward] | ||||
Beginning Balance | $ 2.5 | |||
Restructuring and related costs | $ 3.2 | $ 3.7 | 6 | $ 5.9 |
Utilized - Cash Payments | (6.8) | |||
Ending Balance | 1.7 | 1.7 | ||
Employee Severance [Member] | ||||
Restructuring Reserve [Roll Forward] | ||||
Beginning Balance | 1.7 | |||
Restructuring and related costs | 2.8 | |||
Utilized - Cash Payments | (2.9) | |||
Ending Balance | 1.6 | 1.6 | ||
Other Restructuring [Member] | ||||
Restructuring Reserve [Roll Forward] | ||||
Beginning Balance | 0.8 | |||
Restructuring and related costs | 3 | |||
Utilized - Cash Payments | (3.7) | |||
Ending Balance | 0.1 | 0.1 | ||
Asset Impairment and Accelerated Depreciation [Member] | ||||
Restructuring Reserve [Roll Forward] | ||||
Beginning Balance | 0 | |||
Restructuring and related costs | 0.2 | |||
Utilized - Cash Payments | (0.2) | |||
Ending Balance | $ 0 | $ 0 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Income Tax Disclosure [Abstract] | ||||
Income tax provision | $ 7 | $ 3.9 | $ 11.5 | $ 8.9 |
Earnings before income taxes | $ 26 | $ 27.1 | $ 42.4 | $ 43.3 |
Effective tax rate | 26.90% | 14.40% | 27% | 2,050% |
Earnings per Share (Schedule of
Earnings per Share (Schedule of Weighted-Average Shares Outstanding) (Details) - shares shares in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Schedule Of Weighted Average Number Of Shares [Line Items] | ||||
Basic weighted-average shares outstanding (in shares) | 51.4 | 53.6 | 51.5 | 54 |
Effect of dilutive securities (in shares) | 0.6 | 0.7 | 0.5 | 0.6 |
Diluted weighted-average shares outstanding (in shares) | 54.3 | 52 | 54.6 | |
RSE and PRSE awards | ||||
Schedule Of Weighted Average Number Of Shares [Line Items] | ||||
Effect of dilutive securities (in shares) | 0.6 | 0.7 | 0.5 | 0.6 |
Share options | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Anti-dilutive awards excluded from the calculation of diluted weighted-average shares outstanding (in shares) | 1.2 | 0.8 | ||
RSE and PRSE awards | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Anti-dilutive awards excluded from the calculation of diluted weighted-average shares outstanding (in shares) | 0.1 |
Goodwill and Intangible Asset_2
Goodwill and Intangible Assets (Schedule of Goodwill) (Details) - USD ($) $ in Millions | 6 Months Ended | |
Mar. 31, 2023 | Sep. 30, 2022 | |
Goodwill [Line Items] | ||
Goodwill, Gross | $ 1,704.6 | $ 1,693.2 |
Accumulated goodwill impairment loss | 371 | 371 |
Goodwill [Roll Forward] | ||
Beginning balance | 1,322.2 | |
Cumulative translation adjustment | (11.4) | |
Ending balance | 1,333.6 | |
Wet Shave | ||
Goodwill [Line Items] | ||
Goodwill, Gross | 1,142.5 | 1,133.5 |
Accumulated goodwill impairment loss | 369 | 369 |
Goodwill [Roll Forward] | ||
Beginning balance | 764.5 | |
Cumulative translation adjustment | (9) | |
Ending balance | 773.5 | |
Sun and Skin Care | ||
Goodwill [Line Items] | ||
Goodwill, Gross | 356 | 354.5 |
Accumulated goodwill impairment loss | 2 | 2 |
Goodwill [Roll Forward] | ||
Beginning balance | 352.5 | |
Cumulative translation adjustment | (1.5) | |
Ending balance | 354 | |
Feminine Care | ||
Goodwill [Line Items] | ||
Goodwill, Gross | 206.1 | 205.2 |
Accumulated goodwill impairment loss | 0 | $ 0 |
Goodwill [Roll Forward] | ||
Beginning balance | 205.2 | |
Cumulative translation adjustment | (0.9) | |
Ending balance | $ 206.1 |
Goodwill and Intangible Asset_3
Goodwill and Intangible Assets (Schedule of Amortizable Intangible Assets) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | Sep. 30, 2022 | |
Finite-Lived Intangible Assets [Line Items] | |||||
Amortizable intangible assets, gross carrying amount | $ 686.3 | $ 686.3 | $ 684.3 | ||
Amortizable intangible assets, accumulated amortization | 290.8 | 290.8 | 274.7 | ||
Amortizable intangible assets, net | 395.5 | 395.5 | 409.5 | ||
Amortization of intangibles | 7.7 | $ 7.9 | 15.4 | $ 14 | |
Amortizable intangible assets, amortization expense, remainder of 2023 | 15.4 | 15.4 | |||
Amortizable intangible assets, amortization expense, fiscal 2024 | 30.7 | 30.7 | |||
Amortizable intangible assets, amortization expense, fiscal 2025 | 30.7 | 30.7 | |||
Amortizable intangible assets, amortization expense, fiscal 2026 | 30.5 | 30.5 | |||
Amortizable intangible assets, amortization expense, fiscal 2027 | 30.4 | 30.4 | |||
Amortizable intangible assets, amortization expense, fiscal 2028 | 30.3 | 30.3 | |||
Amortizable intangible assets, amortization expense, after fiscal 2028 | 227.5 | 227.5 | |||
Indefinite-lived Intangible Assets [Line Items] | |||||
Indefinite-lived intangible assets | 594.6 | 594.6 | 587.1 | ||
Trade names and brands | |||||
Finite-Lived Intangible Assets [Line Items] | |||||
Amortizable intangible assets, gross carrying amount | 339.7 | 339.7 | 339.4 | ||
Amortizable intangible assets, accumulated amortization | 80.4 | 80.4 | 72.2 | ||
Amortizable intangible assets, net | 259.3 | 259.3 | 267.2 | ||
Technology and patents | |||||
Finite-Lived Intangible Assets [Line Items] | |||||
Amortizable intangible assets, gross carrying amount | 78.5 | 78.5 | 77.8 | ||
Amortizable intangible assets, accumulated amortization | 76 | 76 | 75 | ||
Amortizable intangible assets, net | 2.5 | 2.5 | 2.8 | ||
Customer related and other | |||||
Finite-Lived Intangible Assets [Line Items] | |||||
Amortizable intangible assets, gross carrying amount | 268.1 | 268.1 | 267.1 | ||
Amortizable intangible assets, accumulated amortization | 134.4 | 134.4 | 127.5 | ||
Amortizable intangible assets, net | $ 133.7 | $ 133.7 | $ 139.6 |
Supplemental Balance Sheet In_3
Supplemental Balance Sheet Information (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 |
Inventories | ||
Raw materials and supplies | $ 95.3 | $ 80.4 |
Work in process | 99.1 | 103.2 |
Finished products | 346.1 | 265.7 |
Total inventories | 540.5 | 449.3 |
Other Current Assets | ||
Prepaid expenses | 75.1 | 70.2 |
Value added tax receivables | 42.4 | 52.7 |
Income taxes receivable | 20 | 19.3 |
Other | 15.2 | 25.1 |
Total other current assets | 152.7 | 167.3 |
Property, Plant and Equipment | ||
Land | 18.7 | 18 |
Buildings | 143.3 | 140.3 |
Machinery and equipment | 1,093.5 | 1,050 |
Capitalized software costs | 59.5 | 56.5 |
Construction in progress | 38.9 | 47 |
Total gross property, plant and equipment | 1,353.9 | 1,311.8 |
Accumulated depreciation and amortization | (1,011.6) | (966.3) |
Total property, plant and equipment, net | 342.3 | 345.5 |
Other Current Liabilities | ||
Accrued advertising and sales promotion | 44.8 | 34.9 |
Short term lease obligation | 9 | 8.8 |
Other | 257.6 | 256.8 |
Total other current liabilities | 302.4 | 291.7 |
Other Liabilities | ||
Pensions and other retirement benefits | 58.3 | 57.9 |
Noncurrent lease obligation | 41 | 41.5 |
Other | 109.1 | 115.7 |
Total other liabilities | $ 167.4 | $ 173.6 |
Leases (Summary of Lease Inform
Leases (Summary of Lease Information) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | Sep. 30, 2022 | ||
Leases [Abstract] | ||||||
Operating lease, right-of-use asset | $ 49.6 | $ 49.6 | $ 50.1 | |||
Short term lease obligation | 9 | 9 | 8.8 | |||
Noncurrent lease obligation | 41 | 41 | 41.5 | |||
Total lease obligation | $ 50 | $ 50 | $ 50.3 | |||
Operating lease, weighted average remaining lease term | 10 years | 10 years | 10 years | |||
Operating lease, weighted average discount rate, percent | 6.70% | 6.70% | 6.60% | |||
Operating lease, expense | $ 3.1 | [1] | $ 3.3 | $ 6.1 | $ 6.8 | |
Right-of-use asset obtained in exchange for operating lease liability | 0.5 | 2.4 | 1.5 | 2.9 | ||
Operating lease, payments | $ 3 | $ 3.3 | $ 6 | $ 6.9 | ||
[1]Lease expense is included in Cost of products sold or SG&A expense based on the nature of the lease. Short-term lease expense is not considered material and is, therefore, excluded from this amount. |
Leases (Operating Lease Payment
Leases (Operating Lease Payment Schedule) (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 |
Leases [Abstract] | ||
Lessee, operating lease, payment due current year | $ 5.6 | |
Lessee, operating lease, payment due year two | 10.1 | |
Lessee, operating lease, payment due year three | 9.1 | |
Lessee, operating lease, payment due year four | 7.6 | |
Lessee, operating lease, payment due year five | 5.8 | |
Lessee, operating lease, payment due after year five | 36.8 | |
Lessee, operating lease, payments due | 75 | |
Lessee, operating lease, undiscounted excess amount | 25 | |
Total lease obligation | $ 50 | $ 50.3 |
Operating lease, weighted average remaining lease term | 10 years | 10 years |
Accounts Receivable Facility (N
Accounts Receivable Facility (Narrative) (Details) - Accounts receivable sales agreement - USD ($) $ in Millions | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Sep. 30, 2022 | |
Transfer of Financial Assets Accounted for as Sales [Line Items] | |||
Accounts receivable sold through AR Facility | $ 315.5 | $ 527.6 | |
Transfer of accounts receivable, sales amount derecognized | 141.1 | $ 78.7 | |
Loss on sale of accounts receivable | $ 1.5 | $ 2.4 |
Debt (Details)
Debt (Details) - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 | |
Debt Instrument [Line Items] | |||
Total long-term debt | $ 1,426 | $ 1,405 | |
Long-term debt | 1,413.6 | 1,391.4 | |
Notes payable | 21.5 | 19 | |
Unamortized debt issuance costs | 12.4 | [1] | 13.6 |
Senior notes | Senior Notes, Due 2028 | |||
Debt Instrument [Line Items] | |||
Total long-term debt | 750 | 750 | |
Unamortized debt issuance costs | 7.6 | 8.3 | |
Senior notes | Senior Notes, Due 2029 | |||
Debt Instrument [Line Items] | |||
Total long-term debt | 500 | 500 | |
Unamortized debt issuance costs | 4.8 | 5.3 | |
Revolving credit facility | |||
Debt Instrument [Line Items] | |||
Total long-term debt | $ 176 | [2] | $ 155 |
[1]As of March 31, 2023, the balance for the Senior Notes due 2028 and the Senior Notes due 2029 are reflected net of debt issuance costs of $7.6 and $4.8, respectively. As of September 30, 2022, the balance for the Senior Notes due 2028 and the Senior Notes due 2029 are reflected net of debt issuance costs of $8.3 and $5.3, respectively.[2]The U.S. revolving credit facility matures in April 2025. |
Retirement Plans (Details)
Retirement Plans (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Retirement Benefits [Abstract] | ||||
Service cost | $ 0.4 | $ 1 | $ 0.9 | $ 2 |
Interest cost | 5.4 | 2.6 | 10.6 | 5.2 |
Expected return on plan assets | (5.5) | (5.3) | (10.9) | (10.6) |
Recognized net actuarial loss | 0.4 | 1.6 | 0.8 | 3.1 |
Net periodic cost (income) | 7.9 | $ (0.1) | 8.6 | $ (0.3) |
Defined benefit settlement loss | $ 7.2 | $ 7.2 |
Equity (Details)
Equity (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | |||
Feb. 03, 2023 | Dec. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | Jan. 26, 2018 | |
Equity [Abstract] | |||||
Share repurchase authorization | 10 | ||||
Treasury shares repurchased (in shares) | 0.8 | ||||
Treasury shares repurchased (in usd) | $ 15 | $ 30 | $ 24.5 | ||
Share repurchase authorization, remaining | 5.7 | ||||
Dividends declared | $ 16.2 | ||||
Dividends to common shareholders | $ 16.1 | $ 16.7 | |||
Dividends declared (per share) | $ 0.15 | $ 0.15 |
Accumulated Other Comprehensi_3
Accumulated Other Comprehensive Loss (Schedule of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | ||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | $ (216.1) | $ (136.9) | |
OCI before reclassifications | [1] | 54.5 | (14.8) |
Reclassifications to earnings | 1.9 | 0.4 | |
Ending balance | (159.7) | (151.3) | |
Foreign Currency Translation Adjustments | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | (131.2) | (41.8) | |
OCI before reclassifications | [1] | 60.1 | (15.9) |
Reclassifications to earnings | 0 | 0 | |
Ending balance | (71.1) | (57.7) | |
Pension and Post-retirement Activity | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | (92.6) | (97.3) | |
OCI before reclassifications | [1] | (1.6) | (2.2) |
Reclassifications to earnings | 5.9 | 2.3 | |
Ending balance | (88.3) | (97.2) | |
Hedging Activity | |||
AOCI Attributable to Parent, Net of Tax [Roll Forward] | |||
Beginning balance | 7.7 | 2.2 | |
OCI before reclassifications | [1] | (4) | 3.3 |
Reclassifications to earnings | (4) | (1.9) | |
Ending balance | $ (0.3) | $ 3.6 | |
[1]OCI is defined as other comprehensive income (loss). |
Accumulated Other Comprehensi_4
Accumulated Other Comprehensive Loss (Schedule of Reclassifications out of Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
Amortization of defined benefit pension and postretirement items, settlement loss, before tax | $ (7.2) | $ (7.2) | ||||
Reclassifications to earnings | (1.9) | $ (0.4) | ||||
Reclassification out of Accumulated Other Comprehensive Income | ||||||
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||
OCI Cash flow hedges reclass to earnings, before tax | 0.8 | $ 1.6 | ||||
OCI Cash flow hedge, reclassification to earnings, tax | 0.2 | 0.5 | 1.8 | 1 | ||
Other comprehensive income, reclassification to earnings, cash flow hedges, after tax | 0.6 | 1.1 | 4 | 1.9 | ||
Amortization of defined benefit pension and postretirement items, actuarial losses, before tax | (0.4) | [1] | (1.6) | [1] | (0.8) | (3.1) |
Amortization of defined benefit pension and postretirement items, tax | (2) | (0.4) | (2.1) | (0.8) | ||
Amortization of defined benefit pension and postretirement items, after tax | (5.6) | (1.2) | (5.9) | (2.3) | ||
Reclassifications to earnings | $ (5) | $ (0.1) | $ (1.9) | $ (0.4) | ||
[1]These AOCI components are included in the computation of net periodic cost. See Note 11 of Notes to Condensed Consolidated Financial Statements. |
Financial Instruments and Ris_3
Financial Instruments and Risk Management (Narrative) (Details) $ in Millions | Mar. 31, 2023 USD ($) contracts | Sep. 30, 2022 USD ($) |
Derivative [Line Items] | ||
Long-term debt | $ 1,426 | $ 1,405 |
Fixed rate | ||
Derivative [Line Items] | ||
Long-term debt | 1,250 | 1,250 |
Fair value of long-term debt | $ 1,030 | 945.9 |
Not designated as hedge | FX contract | ||
Derivative [Line Items] | ||
Open foreign currency contracts | contracts | 8 | |
Derivative, notional amount | $ 69.9 | |
Cash flow hedge | Designated as hedge | FX contract | ||
Derivative [Line Items] | ||
Estimated fair value of derivative | $ (0.3) | $ 11.3 |
Open foreign currency contracts | contracts | 64 | |
Derivative, notional amount | $ 114.1 |
Financial Instruments and Ris_4
Financial Instruments and Risk Management (Schedule of Fair Values of Derivative Instruments) (Details) - FX contract - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 | |
Not designated as hedge | |||
Derivatives, Fair Value [Line Items] | |||
Estimated fair value of derivatives | [1] | $ (0.3) | $ 2 |
Cash flow hedge | Designated as hedge | |||
Derivatives, Fair Value [Line Items] | |||
Estimated fair value of derivatives | [1] | $ (0.3) | $ 11.3 |
[1]erivative assets are presented in Other current assets or Other assets. Derivative liabilities are presented in Other current liabilities or Other liabilities. |
Financial Instruments and Ris_5
Financial Instruments and Risk Management (Schedule of Gains and Losses on Derivative Instruments) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | ||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||
Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration] | Nonoperating Income (Expense) | Nonoperating Income (Expense) | |||||
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] | Nonoperating Income (Expense) | ||||||
FX contract | Designated as hedge | Cash flow hedge | |||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||
Gain (loss) recognized in OCI | $ 1.3 | [1] | $ 3.1 | [1] | $ (5.8) | $ 4.9 | |
Gain (loss) reclassified from AOCI into income (effective portion) | [1],[2] | $ 0.9 | $ 1.6 | ||||
FX contract | Designated as hedge | Cash flow hedge | Other expense (income), net | |||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||
Derivative Instrument, Gain (Loss) Reclassified from AOCI into Income, Effective Portion, Statement of Income or Comprehensive Income [Extensible Enumeration] | |||||||
FX contract | Not designated as hedge | Other expense (income), net | |||||||
Derivative Instruments, Gain (Loss) [Line Items] | |||||||
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] | |||||||
[1]Each of these derivative instruments had a high correlation to the underlying exposure being hedged for the periods indicated and have been deemed highly effective by the Company in offsetting associated risk.[2]Gain was recorded in Other expense (income), net. |
Financial Instruments and Ris_6
Financial Instruments and Risk Management (Schedule of Offsetting Assets and Liabilities) (Details) - FX contract - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 | |
Derivative [Line Items] | |||
Gross amounts of recognized assets | [1] | $ 1.8 | $ 13.4 |
Gross amounts of recognized liabilities | [2] | (3) | (0.5) |
Gross amounts offset in the balance sheet | [1] | (0.1) | 0 |
Gross amounts offset in the balance sheet | [2] | 0.7 | 0.4 |
Net amounts of assets presented in the balance sheet | [1] | 1.7 | 13.4 |
Net amounts of liabilities presented in the balance sheet | [2] | $ (2.3) | $ (0.1) |
[1]All derivative assets are presented in Other current assets or Other assets.[2]All derivative liabilities are presented in Other current liabilities or Other liabilities. |
Financial Instruments and Ris_7
Financial Instruments and Risk Management (Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis) (Details) - Recurring fair value measurement - Level 2 - USD ($) $ in Millions | Mar. 31, 2023 | Sep. 30, 2022 |
Derivative [Line Items] | ||
Deferred compensation liability | $ (19) | $ (21.8) |
Derivatives - foreign currency contracts (liability) asset | (0.6) | 13.3 |
Net liabilities at estimated fair value | $ (19.6) | $ (8.5) |
Segment Data (Schedule of Segme
Segment Data (Schedule of Segment Sales and Profitability) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | |||||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | ||||
Segment Reporting Information [Line Items] | |||||||
Net sales | $ 598.4 | $ 547.7 | $ 1,067.5 | $ 1,011 | |||
Segment profit | 56.2 | 41.7 | 87.5 | 73.5 | |||
Restructuring and related costs | 3.2 | 3.7 | 6 | 5.9 | |||
Acquisition and integration costs | 2 | [1] | 1.1 | [1] | 4.1 | 7.1 | |
Sun Care reformulation costs | 0.6 | 0.2 | [2] | 1.1 | 3.5 | ||
VAT settlement costs | 0 | [3] | 0 | [3] | (3.4) | ||
Other Expenses | (0.5) | (0.5) | |||||
Amortization of intangibles | 7.7 | 7.9 | 15.4 | 14 | |||
Interest and other expense, net | 23 | 14.6 | 37.9 | 30.2 | |||
Restructuring charges | 3 | 3.5 | 5.8 | 5.7 | |||
Earnings before income taxes | 26 | 27.1 | 42.4 | 43.3 | |||
Gain (Loss) Related to Litigation Settlement | (7.2) | (7.2) | 0 | ||||
Wet Shave | |||||||
Segment Reporting Information [Line Items] | |||||||
Net sales | 308.6 | 305 | 583.9 | 591.1 | |||
Segment profit | 35.1 | 27.6 | 70.5 | 79.1 | |||
Sun and Skin Care | |||||||
Segment Reporting Information [Line Items] | |||||||
Net sales | 209.7 | 183.3 | 322.6 | 288.1 | |||
Segment profit | 39.9 | 42.3 | 53 | 46 | |||
Feminine Care | |||||||
Segment Reporting Information [Line Items] | |||||||
Net sales | 80.1 | 59.4 | 161 | 131.8 | |||
Segment profit | 12 | 1.9 | 23.8 | 10.3 | |||
Total Segments | |||||||
Segment Reporting Information [Line Items] | |||||||
Segment profit | 87 | 71.8 | 147.3 | 135.4 | |||
Corporate | |||||||
Segment Reporting Information [Line Items] | |||||||
General corporate and other expenses | $ 17 | $ 17.2 | $ 32.9 | 28 | |||
Cost of products sold | Billie | |||||||
Segment Reporting Information [Line Items] | |||||||
Acquisition and integration costs | $ 0.5 | ||||||
[1]Includes pre-tax SG&A of $0.6 and $6.3 for the three and six months ended March 31, 2022, respectively, for the Acquisition. Additionally, includes Cost of Products Sold of $0.5 and $0.8 related to the valuation of acquired inventory for the Acquisition for the three and six months ended March 31, 2022, respectively. See Note 2 of the Notes to Condensed Consolidated Financial Statements.[2]Includes pre-tax R&D of $0.6 and $1.1 for the three and six months ended March 31, 2023, respectively, and pre-tax Cost of Products Sold of $0.2 and $3.5 for the three and six months ended March 31, 2022, respectively, related to the reformulation, recall and destruction of certain Sun Care products.[3]Includes pre-tax SG&A of $3.4 for the six months ended March 31, 2022 related to the estimated settlement of a prior years’ value-added tax audit of the Company’s German subsidiary. |
Segment Data Segment Data (Sche
Segment Data Segment Data (Schedule of Sales by Geographical Area) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Revenue from External Customer [Line Items] | ||||
Net sales | $ 598.4 | $ 547.7 | $ 1,067.5 | $ 1,011 |
United States | ||||
Revenue from External Customer [Line Items] | ||||
Net sales | 367.9 | 341.9 | 639.7 | 604.4 |
International | ||||
Revenue from External Customer [Line Items] | ||||
Net sales | $ 230.5 | $ 205.8 | $ 427.8 | $ 406.6 |
Segment Data (Schedule of Suppl
Segment Data (Schedule of Supplemental Product Information) (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022 | |
Revenue from External Customer [Line Items] | ||||
Net sales | $ 598.4 | $ 547.7 | $ 1,067.5 | $ 1,011 |
Razors and blades | ||||
Revenue from External Customer [Line Items] | ||||
Net sales | 278.4 | 275.3 | 525.4 | 531 |
Tampons, pads and liners | ||||
Revenue from External Customer [Line Items] | ||||
Net sales | 80.1 | 59.4 | 161 | 131.8 |
Sun care products | ||||
Revenue from External Customer [Line Items] | ||||
Net sales | 153.8 | 131.4 | 201.6 | 171.6 |
Grooming products | ||||
Revenue from External Customer [Line Items] | ||||
Net sales | 38 | 34.4 | 85.3 | 80.7 |
Wipes and other skin care products | ||||
Revenue from External Customer [Line Items] | ||||
Net sales | 17.9 | 17.5 | 35.7 | 35.8 |
Shaving gels and creams | ||||
Revenue from External Customer [Line Items] | ||||
Net sales | $ 30.2 | $ 29.7 | $ 58.5 | $ 60.1 |